Moore v. Regents of University of California

California law protects a competent patient's right to decide whether to undergo medical treatment, and consent is effective only when it is informed. Because the physician-patient relationship is fiduciary in this setting, the physician must disclose information material to the patient's decision rather than unilaterally decide what the patient should be told.

A physician's research or financial stake in a patient's cells can create a conflict of interest. The interest may consciously or unconsciously influence the physician to recommend procedures that are scientifically useful but offer marginal or no medical benefit to the patient. A reasonable patient would regard that possibility as material in deciding whether to consent.

The duty does not prohibit physician-researchers from treating patients or conducting related research. It requires disclosure when an extraneous research or economic interest may affect the physician's judgment. The patient's right to make the ultimate treatment decision outweighs the physician's asserted discretion to withhold such information.

Moore alleged that before the splenectomy Golde had formed an intent and made arrangements to obtain part of Moore's spleen for research, but did not disclose that plan before Moore consented. Those allegations sufficiently pleaded an undisclosed research interest at the time of the surgery.

Moore also alleged that Golde repeatedly represented that later withdrawals of bodily materials were necessary for Moore's health while actively concealing commercial interests in the resulting research. The complaint further alleged that Golde denied the materials had commercial value even after pursuing patent protection. These allegations supported a claim based on the postoperative procedures.

The fact that the splenectomy may have had a genuine therapeutic purpose did not eliminate Golde's disclosure duty. A medically justified procedure may still be influenced by an undisclosed additional motive, and that conflict remains material to the patient's decision.

The Regents, Quan, Genetics Institute, and Sandoz did not themselves stand in a physician-patient fiduciary relationship with Moore and did not themselves have Golde's duty to obtain Moore's informed consent. Their liability therefore could arise only through a recognized secondary-liability theory, such as respondeat superior, agency, or ratification.

The lower courts had not fully resolved the adequacy of Moore's allegations of secondary liability, and the case required further proceedings on other unresolved demurrers. The court therefore did not decide whether Moore could ultimately establish such liability, but allowed him an opportunity to amend his allegations against the nonphysician defendants.

Conversion requires interference with the plaintiff's ownership or possessory right in personal property. Moore did not seek continued possession of his removed cells, and existing California authority did not establish that he retained an ownership interest in excised cells sufficient to support conversion. Statutes governing tissues, organs, blood, and bodily remains treat such materials as a special category rather than ordinary personal property.

The patented cell line and its products were legally and factually distinct from Moore's original cells. Patent law rewards inventive work that creates a patentable cell line, not the discovery of naturally occurring biological material. Moore therefore could not claim ownership of the patented line or of all products derived from it simply because the original cells came from his body.

Extending conversion would impose strict liability on downstream researchers, companies, and repositories that used a cell sample without knowing that the original physician had failed to make adequate disclosures. It would effectively require scientists to investigate the consent history of every sample and would cloud title to research materials used in socially valuable biomedical research.

The court balanced patient autonomy against the risk of inhibiting research and concluded that disclosure-based claims provided the better remedy. Fiduciary-duty and informed-consent claims directly address the physician's conflict of interest without exposing innocent downstream users to strict conversion liability. Broader rules concerning ownership, compensation, or profit-sharing in human tissues involved complex policy choices better addressed by the Legislature.